#United States #Princeton #CytoSorbents #DrugSorb-ATR #Blood Purification

CytoSorbents Corporation Reports Fourth Quarter and Full Year 2025 Results

CytoSorbents Corporation (NASDAQ: CTSO), a pioneering company in the field of blood purification for life-threatening conditions, has announced its financial results for the fourth quarter and the entire year ended December 31, 2025. The company is recognized for its efforts against severe health challenges in intensive care units and cardiac surgeries.

Financial Performance Overview

The financial year of 2025 marked a notable milestone with total revenue hitting $37.1 million, reflecting a 4% growth from the previous year’s $35.6 million. Despite the challenging landscape, the improvement in gross margins, reported at 71%, demonstrates the company’s operational efficiency. Notably, improvements were also recorded in the operating loss, which decreased by 10% to $14.7 million from $16.5 million in 2024. Furthermore, a reduced net loss of $8.2 million indicates a promising trend compared to the previous year's $20.7 million.

In the fourth quarter alone, revenue amounted to $9.2 million, a modest increase of 1% compared to the same period the previous year, despite an 8% decline on a constant currency basis. The gross margin expanded to 74% from 70%, demonstrating enhanced profitability.

Strategic Initiatives

CytoSorbents has executed a strategic workforce and cost reduction program in the fourth quarter, which resulted in a 10% cut in headcount. This move aims to optimize operational processes while aligning expenditures towards achieving cash flow breakeven in 2026. A notable cash balance of $7.8 million as of December 31, 2025, coupled with proceeds from an amended credit facility, supports the company’s operational strategies moving forward.

Clinical and Commercial Momentum

In terms of clinical achievements, CytoSorbents reported that they surpassed 300,000 cumulative CytoSorb® treatments globally, marking over a 50% increase in usage over recent years. The consistent adoption of this therapy across 70 countries indicates its growing relevance in critical care settings. The recent International Symposium of Critical Care and Emergency Medicine (ISICEM) conference featured substantial new clinical data supporting the use of CytoSorb, particularly relating to sepsis and septic shock treatments.

Dr. Phillip Chan, CEO of CytoSorbents, stated, "2025 was a transitional year for our business as we made good progress in our four key objectives. We ended the year with positive clinical and commercial momentum for 2026, positioning us well for the growth ahead."

DrugSorb®-ATR Regulatory Status

CytoSorbents continues to engage proactively with the FDA regarding its DrugSorb-ATR antithrombotic removal system, which received Breakthrough Device designation for mitigating serious perioperative bleeding during CABG surgery in patients on blood thinners. Recent FDA feedback has encouraged the company to pursue a new De Novo application, incorporating real-world data that supports positive safety and efficacy outcomes.

The incorporation of feedback from a formal appeal meeting with the FDA highlighted the company’s commitment to overcoming previous challenges in regulatory submissions, reinforcing the comprehensive safety profile of their technology.

Future Outlook

As CytoSorbents enters 2026, the agenda is clear: to exhibit sustained growth across all sales channels while working towards cash flow breakeven. With a robust pipeline of clinical data and technologies in progress, the company is determined to contribute significantly to global health outcomes in critical care environments.

Dr. Chan concluded, "By leveraging the clinical evidence generated by leading professionals worldwide, we are set on a course that prioritizes improved patient outcomes and operational success. We look forward to providing updates on our continued progress."

Conclusion

The financial results and initiatives conveyed by CytoSorbents indicate not only potential for commercial growth but also underscore a commitment to clinical innovation. As they head into 2026, both internal changes and regulatory advancements position CytoSorbents as a formidable player in the health technology landscape.